Fluuridine for Injection

After injection, this product is converted into active fluorouridine monophosphate synthetase in the body, preventing the methylation of deoxyuridylic acid from converting to deoxythymidylic acid, thereby blocking DNA synthesis and inhibiting RNA formation, leading to tumor cell death.

Chemical name: The main ingredient of this product is fluorouracil, and its chemical name is 5-fluorouracil-2'-deoxynucleoside. Chemical structure: Molecular formula: C9H11FN2O5 Molecular weight: 246.19 Auxiliary materials: mannitol.

This product is a white loose solid and is hygroscopic.

This product is an antimetabolite anti-tumor drug. It is suitable for liver cancer, rectal cancer, esophageal cancer, gastric cancer, breast cancer and lung cancer, etc. It has a significant effect on primary liver cancer that cannot be surgically removed.

Each bottle is dissolved with 2.5ml of injection water to make a solution containing about 100mg of fluuridine per 1ml. It should be appropriately diluted with 5% glucose or 0.9% sodium chloride injection when used. The effect of hepatic artery catheterization in the treatment of liver cancer is better, 250-500mg each time, and the dosage for each course of treatment is in accordance with the doctor's advice. Intravenous drip: generally 15mg/kg per body weight, once a day, drip for 2-8 hours, and use it continuously for 5 days. The dose is then halved and given every other day until toxic reactions occur.

The adverse reactions of this product are usually related to complications of local arterial perfusion. Usually manifested as nausea, vomiting, diarrhea, enteritis, stomatitis and localized erythema. Common experimental abnormalities are: anemia, leukopenia, elevated alkaline phosphatase, serum transaminase, serum bilirubin and lactate dehydrogenase, most of which return to normal after continued medication or reduction or discontinuation of medication. Other adverse reactions are: Gastrointestinal: duodenal ulcer, duodenitis, gastritis, bleeding, gastroenteritis, glossitis, pharyngitis, anorexia, cramps, abdominal pain, and possible hepatobiliary cirrhosis. Skin diseases: alopecia, nonspecific skin toxicity, rash. Cardiovascular: myocardial ischemia. Various clinical reactions: fever, drowsiness, malaise, weakness. Complications caused by local arterial perfusion: aneurysm, arterial ischemia, arterial thrombosis, embolism, fibromyositis, thrombophlebitis, liver necrosis, abscess, catheter infection, catheter bleeding, catheter obstruction, leakage.

1. Patients with a history of severe allergic symptoms to this product are contraindicated. 2. Patients with suppressed bone marrow function are contraindicated. 3. Pregnant women are contraindicated. 4. Malnourished patients are contraindicated. 5. Patients with potential severe infections are contraindicated.

Precautions for children: The safety and effectiveness of this product for children have not been determined. Precautions for pregnancy and lactation: This product has teratogenic effects on chicken embryos, mice (2.5-100 mg/kg) and rats (75-150 mg/kg), including: cleft palate, bone defects, abnormal appendages, claws and tails. The dose that causes teratogenicity in animals is 4.2-125 times the recommended human dose. There is no evidence that fluridine is teratogenic to humans, but because other drugs that inhibit DNA synthesis (such as methotrexate and aminopterin) have been reported to be teratogenic to humans, pregnant women can only use this product when the benefits of the drug outweigh its potential harm to the fetus. It is not clear whether fluridine is excreted in breast milk. Because this product inhibits the synthesis of DNA and RNA, it is contraindicated for lactating women. Precautions for the elderly: It is not yet clear.

Not yet clear

Protect from light, seal tightly, and store in a cool and dry place.

0.5g

36 months

Han Hui Pharmaceuticals Company Limited

• Founded in:

  2012-09-06

• Address:

  No. 2 Haizheng Road, Xukou Town, Fuyang District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330100053653670B

• Registered Funds:

  1852.03035908 yuan

• Website:

  Log in to view

• Email:

  Log in to view